A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01316887 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

563

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: 125/25 mcg once-daily GSK573719/GW642444
DRUG: 125mcg once-daily GSK573719
DRUG: Placebo once-daily

Sponsor

GlaxoSmithKline